Bailisi Kang Biomedicine (Hangzhou)

Bailisi Kang Biomedicine, also known as Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (BlissBio), is a clinical-stage biopharmaceutical company founded in December 2017 by pharmaceutical veterans Dr. Ziping Wei and Yu Hong Zhou in Hangzhou, China. The company focuses on the discovery, development, and commercialization of anti-tumor biotherapeutics, with a specialization in antibody-drug conjugates (ADCs). The core team has experience in developing various biotherapeutics, including monoclonal antibodies, bispecific antibodies, and ADCs, with nine products they contributed to receiving market approval.

BlissBio's business model centers on its proprietary and patented ADC technology platform, developing a pipeline of oncology drugs to address unmet medical needs. The company has its own GMP-certified manufacturing facility capable of producing antibodies and ADCs for clinical trials and early-stage commercialization. Its revenue model involves strategic collaborations, licensing agreements, and milestone payments. A key partnership is with the Japanese pharmaceutical firm Eisai Co., Ltd. In May 2023, the two companies entered into a joint development and strategic collaboration agreement for BlissBio's leading product, BB-1701. The agreement includes upfront payments, milestone payments that could total up to $2 billion, and royalties on sales. Eisai gained global development and commercialization rights for BB-1701, excluding Greater China.

The company's main product candidate, BB-1701, is an ADC that targets the HER2 protein, which is expressed in various solid tumors like breast and lung cancer. It combines an anti-HER2 antibody with Eisai's anticancer agent, eribulin, as the payload. BB-1701 is currently in Phase I/II international clinical trials in the U.S. and China. The company's pipeline also includes other ADC candidates like BB-1705, which targets EGFR for solid tumors, and BB-1712, targeting B7-H3, both of which are in clinical development. BlissBio has successfully raised capital to fund its research and development, including a Series B round of $61.3M in April 2021 and a Series B++ financing from Eisai in June 2023.

Keywords: antibody-drug conjugates, oncology therapeutics, biopharmaceuticals, clinical-stage biotech, tumor-targeting therapy, HER2-positive cancers, solid tumors, cancer research, monoclonal antibodies, immunotherapy, eribulin, BB-1701, ADC technology platform, biotherapeutics development, pharmaceutical manufacturing, oncology drug pipeline, cancer treatment, clinical trials, drug discovery, Ziping Wei